C
C. Zimpfer-Rechner
Researcher at German Cancer Research Center
Publications - 2
Citations - 471
C. Zimpfer-Rechner is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Dacarbazine & Phases of clinical research. The author has an hindex of 2, co-authored 2 publications receiving 453 citations.
Papers
More filters
Journal ArticleDOI
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
Dirk Schadendorf,Selma Ugurel,Beatrice Schuler-Thurner,Frank O. Nestle,Alexander Enk,Eva-B. Bröcker,Stephan Grabbe,Werner Rittgen,Lutz Edler,Antje Sucker,C. Zimpfer-Rechner,Thomas G. Berger,Jivko Kamarashev,G. Burg,Helmut Jonuleit,A. Tüttenberg,Jürgen C. Becker,Petra Keikavoussi,Eckhart Kämpgen,Eckhart Kämpgen,Gerhard Schuler +20 more
TL;DR: DC vaccination could not be demonstrated to be more effective than DTIC chemotherapy in stage IV melanoma patients, and the observed association of overall performance status and HLA haplotype with overall survival for patients treated by DC vaccination should be tested in future trials employing DC vaccines.
Journal ArticleDOI
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
Wolfram Fink,C. Zimpfer-Rechner,Adina Thoelke,Robert Figl,Martin Kaatz,Selma Ugurel,Dirk Schadendorf +6 more
TL;DR: Liposomal doxorubicin as monotherapy is well tolerated but of limited clinical efficacy, whether the survival benefit of a significant proportion of patients (20%) holds true in larger cohorts and whether the efficacy of liposomalDoxorUBicin can be improved by combinations without compromising the low toxicity profile needs further studies.